JSC Biochimpharm

Beginning in the 1940's G.Eliava Institute of Bacteriophage, Microbiology and Virology produced several types of bacteriophage-based treatments. In 1994 the production group at this Institute separated from the Eliava Institute and formed a new commercial company, JSC Biochimpharm.

JSC proceeded to restore mass production of several classic phage preparations, rennovating the bacterial strain and phage collections, and enhanced these products to address newly emerging antibiotic resistant strains.

Despite a recent history grave economic and political conditions, Biochimpharm now mass produces of two highly effective polyvalent bacteriophage preparations and several monophage preparations. Biochimpharm's manufacturing capabilities are the world's best in terms of quality, consistency and capacity.

Research Center for Medical Polymers and Biomaterials
Tbilisi, Georgia

Biomedical applications of new polymers as absorbable surgical devices and drug sustained/controlled release systems.

Evergreen State College, Olympia, Washington, USA

Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Science - Wroclaw, Poland

Immune System Development and Function: Immune Centre Combines Research and Education with Clinical Practice.

G. Eliava Institute of Bacteriophages, Microbiology and Virology, Tbilisi, Georgia

In its heyday in the 1970s and 80s, nearly 800 people worked in the Industrial Branch of the Eliava Institute, using enormous vats, pill stampers and automatic bottling machines to pump out tons of phage products for military and civilian uses all over the Soviet Union.  Another 200 worked to analyze hundreds of thousands of bacterial samples that continuously poured in at the direction of the Soviet Ministry of Health, testing the phage cocktails for efficacy and constantly isolating new phage and making refinements.   They also fought infectious disease in other ways - vaccines, immune enhancers, probiotic bacterial cultures - but phage were their main focus.  By then, Institutes and factories in places like Gorki and Ufa were also producing these phage products for Soviet use, but Tbilisi phage were especially prized as far away as Lithuania even in 1990.

Collaborators in Bacteriophage and Medical Polymers Research

• University of Maryland, Baltimore, MD (USA)
• Cornell University, Ithaca, NY (USA)
• University of Akron, Akron, OH (USA)
• University of Georgia, Atlanta, GE (USA)
• Chubu University, Kasugai, Aichi (Japan)
• University of Hamburg, Hamburg (Germany)
• Institute of Organic Chemistry of Ukrainian Academy of Sciences, Kiev, The Ukraine
• A. N. Nesmeyanov Institute of Organometallic Compounds of RAS, Moscow (Russian Federation)
• Nuclear Physics Institute at Tomsk Polytechnic University of the Ministry of Education, Tomsk (Russian Federation)
• Institute of Biomedical Problems RAS, Moscow (Russian Federation)
• Tbilisi National University, Tbilisi (Georgia)
• Intralytix, Inc., Baltimore, MD (USA)
• MediVas LLC, San Diego, CA (USA)
• STRATEC Medical, Oberdorf, Switzerland